A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men
Nima Soleymanlou, Yoshifumi Tachibana, Takuma Yonemura, Silke Retlich et al.
Citations
3 citations
Journal
Expert Opinion on Investigational Drugs
Topics
Ion Channels and Receptors
Field-Weighted Citation Impact (FWCI)
4.39
article
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men
Nima Soleymanlou, Yoshifumi Tachibana, Takuma Yonemura, Silke Retlich, Akiko Sarashina